JDRF forms partnership with M...( drugs treatments technologies and ot...)

drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications. Funding for the Protg trial will be paid in installments triggered by specific milestones within the clinical trial. The Protg trial will assess the effectiveness, tolerance, and safety of teplizumab in three different dosing regimens in children and adults with recent-onset type 1 diabetes. The goal of the trial is to assess teplizumab's capacity to reduce insulin requirements, while maintaining relatively normal blood sugar levels. Additional information regarding the Protg trial can be found on the www.clinicaltrials.gov website (type "MacroGenics" or "NCT00385697" in the "Search" field).

"We are delighted to partner with JDRF, and we hope that with their support of Dr. Herold's research and the Protg trial, we will be able to better understand the therapeutic potential of teplizumab and how the compound acts to preserve beta cell function in recently diagnosed type 1 diabetes patients," said MacroGenics President and Chief Executive Officer Scott Koenig, M.D., Ph.D. "As the world's leading charitable organization that funds type 1 diabetes research, JDRF's mission is to support the best and most promising research being done in this area. Their confidence in teplizumab and financial support of our clinical program is of great value to us and we hope it will accelerate MacroGenics' progress with this promising new compound."

About teplizumab and Anti-CD3

Anti-CD3 antibodies such as teplizumab (MGA031, hOKT3-gamma-1 (Ala-Ala)) are engineered to block the function of CD3 cells; immune T cells that orchestrate the destruction of islets. The antibodies prevent "activation" of the T cells after they have identified their target, disarming them once they are poised to attack. Teplizumab is a humanized monoclonal antibody that binds to an epit
'"/>

Contact: Eileen Brangan Mell
ebrangan@jdrf.org
212-479-7577
Juvenile Diabetes Research Foundation International
3-Jan-2007

Page: 1 2 3 4
Related biology news :

1. Toward improved forms of a time-tested cholesterol-fighter
2. Creating new life forms that may help eradicate cancer affecting women
3. Chromium picolinate shows greater benefits in diabetes care than other forms of chromium
4. Low-pathogenic forms of bird flu do cause illness among birds
5. National Science Foundation supports UCR study of polar lake life forms
6. Scientists discover new life forms in the Arctic Ocean
7. The CReSA is working on a new strategy to combat spongiforms
8. Figuring out function from bacterias bewildering forms
9. Studies show that rockfish thrive with offshore platforms as their home base
10. How the octopus forms an elbow
11. UCSD forms stem cell collaboration with major Australian centers